Metastatic Triple-Negative Breast Cancer

Welcome to the Metastatic Triple-Negative Breast Cancer Resource Center! Our goal is to provide current information, news, literature, and other resources in this important area of oncology for you and your patients. If you have any feedback or questions, please contact editor@advancedpractitioner.com

Jacquelyn Lauria, RN, APN, AOCNP
Stacy Goldstein Breast Center
Rutgers Cancer Institute of New Jersey

NCCN Guidelines for Patients: Breast Cancer - Invasive

The Landscape of Targeted Therapies in TNBC

Triple Negative Breast Cancer Molecular Subtyping and Treatment Progress

Update on Triple-Negative Breast Cancer Disparities for the United States: A Population-Based Study From the United States Cancer Statistics Database, 2010 Through 2014

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Metastatic Triple-Negative Breast Cancer Resource Center

Interview With Coral Omene, MD, PhD. Key Clinical Data in mTNBC: Updates from SABCS, Part 2

NCCN Guidelines for Patients: Breast Cancer - Invasive

The Landscape of Targeted Therapies in TNBC

Triple Negative Breast Cancer Molecular Subtyping and Treatment Progress

Update on Triple-Negative Breast Cancer Disparities for the United States: A Population-Based Study From the United States Cancer Statistics Database, 2010 Through 2014

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Biomarker Insights

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker

Breast Cancer Research and Treatment

Immunotherapy Toxicity: Identification and Management

Drug Discovery Today

Triple-Negative Breast Cancer Brain Metastasis: An Update on Druggable Targets, Current Clinical Trials, and Future Treatment Options

Annals of Translational Medicine

Severe Immune-Related Hepatitis and Myocarditis Caused by PD-1 Inhibitors in the Treatment of Triple-Negative Breast Cancer: A Case Report

The ASCO Post

ASCO Updated Guideline of Biomarkers in Metastatic Breast Cancer Supports PIK3CA, BRCA1/2, PD-L1 Testing

Expert Opinion on Biological Therapy

Harmonizing PD-L1 Testing in Metastatic Triple Negative Breast Cancer

Cancer Reports

Ethnic Disparities in the Immune Microenvironment of Triple Negative Breast Cancer and Its Role in Therapeutic Outcomes

Future Medicine

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Case Reports in Oncology

Neutropenic Enterocolitis: A Rare Complication of Sacituzumab Govitecan

Cancer Treatment Reviews

Optimizing Choices and Sequences in the Diagnostic-Therapeutic Landscape of Advanced Triple-Negative Breast Cancer: An Italian Consensus Paper and Critical Review

Fast Facts #6: Immunotherapy and Endocrinopathies